...$20.9M in 4Q13. The 4Q14 revenue figure includes $8.2M from the February 2014 acquisition of DVS Sciences Inc....

...which should be positives for the microfluidics company. He also said the February acquisition of DVS Sciences Inc....

...single cell gene expression analysis tools remains strong." He also said Fluidigm's February acquisition of DVS Sciences Inc....

...Microfluidics company Fluidigm completed its acquisition of DVS Sciences, which develops and markets single-cell protein analysis systems...
...cash and stock deal (see BioCentury, Feb. 3). Fluidigm Corp. (NASDAQ:FLDM), South San Francisco, Calif. DVS Sciences Inc....

...increased concentration in sample preparation vs. the higher revenue-generating analytical tools base. Fluidigm is acquiring DVS Sciences Inc....

...Microfluidics company Fluidigm is acquiring DVS Sciences for about $207.5 million in a cash and stock deal...
...& Watkins LLP is the company's legal advisor. Fluidigm Corp. (NASDAQ:FLDM), South San Francisco, Calif. DVS Sciences Inc....

...A quick turnaround from first financing to takeout netted investors in DVS Sciences Inc. an impressive return in...

...Microfluidics company Fluidigm Corp. (NASDAQ:FLDM) is acquiring DVS Sciences Inc. (Sunnyvale, Calif.) for about $207.5 million in a...

...and metabolic pathways in cancer cells. The method used in the paper is marketed by DVS Sciences Inc....
...5(36); doi:10.1038/scibx.2012.968 Published online Sept. 13, 2012 Flow cytometry method covered by patents owned by DVS Sciences...

...to find partners to develop and commercialize treatments for cancer and autoimmune indications using SCNP. DVS Sciences Inc....
...is on DVS's scientific advisory board. Companies and Institutions Mentioned Celgene Corp. (NASDAQ:CELG), Summit, N.J. DVS Sciences Inc....